Rituximab (Chimeric Anti-CD20 Antibody) for Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation in Adults: Long-Term Experience from a Single Center

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Transplantation

• Publication date

  2005-12-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.tp.0000185570.41571.dfPMID 16378063
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era

  2005cited by this paper
• A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.

  2003cited by this paper
• Humanized anti‐CD20 monoclonal antibody (Rituximab) treatment for post‐transplant lymphoproliferative disorder *

  2003cited by this paper
• European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment.

  2002cited by this paper
• Posttransplant Lymphoproliferative Disorders in Liver Transplantation: A 20-Year Experience

  2002cited by this paper
• Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

  2001cited by this paper
• Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant.

  2001cited by this paper
• Management of Epstein–Barr Virus‐induced Post‐transplant Lymphoproliferative Disease in Recipients of Solid Organ Transplantation

  2001cited by this paper
• The diverse pathology of post‐transplant lymphoproliferative disorders: the importance of a standardized approach

  2001cited by this paper
• Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

  2000cited by this paper
• CD‐20 expression in post‐transplant lymphoproliferative disorders: Treatment with Rituximab

  2000cited by this paper
• Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?

  2000influential reference
• Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using Rituximab

  2000influential reference
• Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.

  2000cited by this paper
• Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies.

  2000cited by this paper
• Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

  2000cited by this paper
• Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases.

  2000cited by this paper
• Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.

  2000cited by this paper
• Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

  1999cited by this paper
• What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

  1999cited by this paper
• [New antitumor drugs for non-Hodgkin's lymphoma].

  1998cited by this paper
• Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.

  1998cited by this paper
• Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop.

  1997cited by this paper
• Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.

  1997cited by this paper
• Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

  1984cited by this paper
• Malignant lymphomas in transplantation patients.

  1969cited by this paper
• Five Years' Experience in Renal Transplantation with Immunosuppressive Drugs: Survival, Function, Complications, and the Role of Lymphocyte Depletion by Thoracic Duct Fistula

  1968cited by this paper

• Post-transplantation Lymphoproliferative Disorder (PTLD): In the Liver Transplant Recipient.

  2023cites this paper
• Management of PTLD after SOT

  2021cites this paper
• Newer developments in viral hepatitis: Looking beyond hepatotropic viruses

  2021cites this paper
• Epstein-Barr virus-associated lymphoproliferative disorders in immunosuppressed patients

  2021cites this paper
• Malignancy Following Lung Transplantation

  2021cites this paper
• Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant

  2020cites this paper
• Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disease

  2019cites this paper
• Medical Course and Complications After Heart Transplantation

  2018cites this paper
• First‐line use of rituximab correlates with increased overall survival in late post‐transplant lymphoproliferative disorders: retrospective, single‐centre study

  2017cites this paper
• Post-transplant lymphoproliferative disorders

  2016cites this paper
• Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children

  2016cites this paper
• Post-transplant lymphoproliferative disorders.

  2015cites this paper
• Epstein-Barr Virus—Associated Posttransplantation Lymphoproliferative Disorder With Tacrolimus Metabolism Deterioration in Infants After Living-Donor Liver Transplantation

  2015cites this paper
• Blood disorders typically associated with renal transplantation

  2015cites this paper
• Managing the challenge of PTLD in liver and bowel transplant recipients

  2015influential citation
• 96. Post-Transplant Lymphoproliferative Disorders

  2014cites this paper
• Posttransplant Lymphoproliferative Disease after Lung Transplantation

  2013cites this paper
• Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation

  2013cites this paper
• Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder

  2013cites this paper
• Post-transplant Lymphoproliferative Diseases: a Case Report and Discussion of Management

  2013cites this paper
• Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies

  2013cites this paper
• Induction Therapy in Renal Transplantation

  2012cites this paper
• Managing Post-Transplant Lymphoproliferative Disorders in Solid-Organ Transplant Recipients

  2012influential citation
• Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

  2012cites this paper
• The KHA-CARI Guidelines Caring for Australasians with Renal Impairment The Kidney Health Australia-Caring for Australasians with Renal Impairment (KHA-CARI) Guidelines Adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

  2012cites this paper
• Update on the role of rituximab in kidney diseases and transplant

  2012cites this paper
• UNGRADED SUGGESTIONS FOR CLINICAL CARE IMPLEMENTATION AND AUDIT

  2012cites this paper
• Immunosuppressive Preconditioning or Induction Regimens

  2012cites this paper
• Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update

  2011cites this paper
• Posttransplant lymphoproliferative disease following liver transplantation

  2011cites this paper
• Update on EBV monitoring, detection and therapy in PTLD after solid organ transplant

  2010cites this paper
• Hematopoietic Stem Cell Transplantation after Posttransplant Lymphoproliferative Disorder

  2010cites this paper
• Post-transplant lymphoproliferative disorders following solid-organ transplantation

  2010cites this paper
• Tonsillectomy in post‐transplant lymphoproliferative disease in children

  2010cites this paper
• Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

  2010cites this paper
• Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: report from the PTLD.Int Survey.

  2010cites this paper
• Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

  2010cites this paper
• Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

  2010cites this paper
• The changing face of post‐transplant lymphoproliferative disease in the era of molecular EBV monitoring

  2010cites this paper
• Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?

  2010cites this paper
• Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines

  2010cites this paper
• Posttransplantation Lymphoproliferative Disorder (PTLD) in Liver and Small Bowel Transplant Recipients

  2010cites this paper
• Treatment of PTLD

  2010cites this paper
• Tonsillectomy in Post-Transplant Lympoproliferative Disease

  2010cites this paper
• Extranodal diffuse large B-cell lymphoma confined to liver in a kidney transplant recipient.

  2010cites this paper
• Immunosuppressive Drugs in Kidney Transplantation

  2009cites this paper
• New Possibilities to Improve the Outcomes of Renal Transplantation

  2009cites this paper
• Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction

  2009cites this paper
• Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.

  2008cites this paper
• Viral nephropathies: core curriculum 2008.

  2008cites this paper
• Pharmacotherapy of post-transplant viral infections

  2008cites this paper
• Monoclonal antibodies in the treatment of malignant lymphomas.

  2008cites this paper
• Chapter 55 – Monoclonal Antibody Therapy of Cancer

  2008cites this paper
• EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial

  2008cites this paper
• Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.

  2008cites this paper
• Pharmacotherapy of post-transplant viral infections.

  2008cites this paper
• Rituximab therapy in malignant lymphoma

  2007cites this paper
• Strategies for Epstein–Barr virus monitoring, detection and therapy in post-transplant lymphoproliferative disorder

  2007cites this paper
• Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series.

  2007cites this paper
• econd Malignancies after Allogeneic Hematopoietic ell Transplantation

  2007cites this paper
• Second malignancies after allogeneic hematopoietic cell transplantation.

  2007cites this paper
• Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

  2007cites this paper
• Presentation and early detection of post‐transplant lymphoproliferative disorder after solid organ transplantation

  2007cites this paper
• Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation

  2007cites this paper
• The emerging role of rituximab in organ transplantation

  2006cites this paper
• Liver transplantation for inborn errors of liver metabolism

  2006cites this paper
• Drug Insight: rituximab in renal disease and transplantation

  2006cites this paper
• Immunosuppressive preconditioning or induction regimens : evidence to date.

  2006cites this paper